Streetbeat News

Stock Prices

CELH

Stifel has maintained its Buy rating on Celsius Holdings (NASDAQ:CELH) but reduced its price target from $191.00 to $64.00. Despite the lowered target, the new price suggests a potential 18.65% upside from the current price of $53.94. Celsius Holdings, with a focus on the energy drink market in North America, has a 20-year distribution agreement with PepsiCo, which owns an 8.5% stake in the company.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:00 pm

ESTC

Goldman Sachs has maintained a Neutral rating for Elastic (NYSE:ESTC) but raised its price target from $83.00 to $93.00. Despite this, Elastic's shares are trading down 0.9% at $109.21, and the new price target suggests a potential decline of 14.84% from the current price. Elastic is a software company that specializes in enterprise search, observability, and security.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:00 pm

ZTS

Over the past 5 years, Zoetis (NYSE:ZTS) has produced an average annual return of 15.54%, outperforming the market by 3.99% on an annualized basis. A $100 investment in ZTS 5 years ago would be worth $200.59 today. Zoetis currently has a market cap of $83.26 billion. The article highlights the impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:00 pm

CBRL

Piper Sandler has maintained a Neutral rating on Cracker Barrel Old (NASDAQ:CBRL) but lowered its price target from $96.00 to $75.00. Cracker Barrel's stock is currently trading at $72.00, down 0.5% over the last 24 hours. The new price target suggests a potential upside of 4.17%. Cracker Barrel operates full-service restaurants in the U.S., with a significant portion of revenue coming from its gift shops. Analyst ratings are provided by financial experts and are subject to error.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:00 pm

ANET

Arista Networks (NYSE:ANET) has significantly outperformed the market, with an average annual return of 30.44% over the past 5 years. A $1000 investment in ANET 5 years ago would be worth $3,564.74 today. Arista Networks currently has a market cap of $66.11 billion.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:00 pm

MRSN

Citigroup has upgraded Mersana Therapeutics (NASDAQ:MRSN) to a Buy rating with a new price target of $5.00, up from the previous target of $1.00. Mersana's shares have risen 5.26% to $2.00 in the last 24 hours. The new price target suggests a potential upside of 150.0% from the current share price. Mersana is a clinical-stage biopharmaceutical company focused on developing targeted drugs with its proprietary ADC platforms.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:00 pm

KRRO

Korro Bio's stock price has increased following a positive initiation of coverage by HC Wainwright & Co., who gave it a Buy rating and set a price target of $100.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 4:55 pm

CVM

CEL-SCI Corporation's stock is trading higher following the announcement that the British National Institute for Health and Care Excellence (NICE) has selected its drug Multikine as a potential new standard of care for head and neck cancer.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 4:52 pm

VINE

Fresh Vine Wine Inc (NASDAQ:VINE) stock dropped 9.5% to $0.71 after announcing a non-binding merger agreement with Notes Live. The merger, expected to close by early 2024, is subject to due diligence, financial conditions, and regulatory approvals. Notes Live will hold a significant portion of VINE's shares post-merger. The deal is not yet finalized, and the stock has fluctuated between a 52-week high of $1.99 and a low of $0.21.

Portfolio Pulse from Henry Khederian

December 04, 2023 | 4:48 pm

CVM

CEL-SCI Corporation (AMEX:CVM) stock is trading higher after the announcement that the British National Institute for Health and Care Excellence (NICE) has selected its drug Multikine to be evaluated as a potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the U.K. The selection is based on phase III clinical trial results indicating a significant 5-year survival benefit. CEL-SCI's CEO Geert Kersten expressed encouragement over this development. CVM shares have surged 41% to $2.92.

Portfolio Pulse from Vandana Singh

December 04, 2023 | 4:45 pm